Researchers at Memorial Sloan Kettering Cancer Center (MSK) have developed some of the first robust laboratory models of a confounding adult-onset inflammatory disease called VEXAS syndrome—shedding new light on its mechanisms ...
Nov 3, 2025
0
16
Researchers at Karolinska Institutet have identified a vulnerability in certain blood cancer cells that makes it possible to eliminate the cancer cells with a drug, without harming healthy cells. The study is published in ...
Sep 2, 2025
0
28
A study from the University of Michigan Health Rogel Cancer Center may have—at last—cracked the cold case of immunotherapy resistance. The research, led by Arul M. Chinnaiyan, M.D., Ph.D., identifies the UBA1 enzyme, already ...
Dec 3, 2024
0
48
New research at ACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, found that JAK inhibitors (JAKi) and tocilizumab elicited better response rates in VEXAS syndrome compared to other targeted ...
Nov 7, 2023
0
38
VEXAS syndrome is a severe autoinflammatory disease that results in a spectrum of rheumatologic and hematologic conditions. Mostly affecting men over age 50, VEXAS is caused by somatic mutations in the UBA1 gene of blood ...
Jul 10, 2023
0
39
Researchers at VCU Massey Cancer Center have set their sights on a new therapeutic target for an aggressive form of breast cancer with limited treatment options.
Oct 25, 2022
0
66
A new research perspective published in Oncoscienceexplores SLFN11's surveillance role in protein homeostasis.
Aug 3, 2022
0
49
